In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Podcast: Identifying The 80% Of Undiagnosed And Misdiagnosed Patients

Executive Summary

Vibhor Gupta, director and founder of Pangaea Data, talks to In Vivo about the value of identifying the 80% of patients with undiagnosed or misdiagnosed conditions, and how his company is addressing this need.

Pangaea Data uses unsupervised AI to comb through over 500 million patient records from a network of data partners to find undiagnosed ones, in a privacy compliant manner.

In this episode, Vibhor Gupta, director and founder of Pangaea Data, talks to In Vivo about his company's platform, successes to date, collaborations and the importance of marrying AI with physician expertise. 

 

Timestamps: 

10 seconds - Introduction

1:05 - Vibhor's story and the history of Pangaea

2:45 - Pangaea's platform, finding undiagnosed patients and case studies

7:00 - What data are shared and how privacy is maintained

10:25 - Collaboration with Microsoft and other cloud providers and connecting to pharma and health care companies

12:05 - Impacts of AI developments on the Pangaea platform and "activating patients" with large language models

13:55 - Harmonizing AI with human expertise 

16:40 - The role of pharma in getting the word out about Pangaea's diagnostic platform 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel